



Curriculum Vitae

Personal
information

Christophe Lahorte

Work
experience

1. Employer: Gent University
 - Start date: 091998
 - End date: 082004
 - Position: Scientific Personnel (Research & Development)
 - Activities: • Research activities in preparation of a PhD. thesis in Pharmaceutical Sciences at the Gent University, PhD. thesis title: "123I-99mTc-labelled Annexin V for in vivo detection of programmed cell death and 123I-MAb 14C5 as potential SPECT ligand for imaging tumours" (September 1998 – April 2004) This research work was conducted in collaboration with the several national and international research groups. During these activities, experience was obtained in research and development, quality control, and (pre)clinical evaluation of radiopharmaceuticals in analytical chemistry and biotechnological and molecular imaging techniques. • Collaborations with pharmaceutical industry: (Radio)chemical development, quality control, release testing and (pre)clinical evaluation of diagnostic radiopharmaceuticals in collaboration with Theseus Imaging Corporation, a division of North American Scientific, Boston, USA (September 2002 – August 2004) These tests were conducted at the Laboratoire de Radiopharmacie (ISO 17025 certified) of the Gent University which is officially recognized as national control laboratory by the Federal Government of Health in Belgium for the quality control and analysis of pharmaceuticals (BS 18.11.1988, MS 18.01.2001) • Set up and performance of pharmaceutical trials in diagnostic oncology and cardiology, in collaboration with the Departments of Nuclear Medicine, Radiotherapy, Head and Neck Surgery, Pathology and Cardiology at the Gent University Hospital, Theseus Imaging Corporation, Boston, USA and Fisher Clinical Services, West Sussex, UK (2001 – August 2004)
 - Country: Belgium
2. Employer: federal agency for medicines and healthcare products (FAMHP)
 - Start date: 092004
 - End date: 032009
 - Position: chemical_pharmaceutical assessor
 - Activities: • Chemical_pharmaceutical assessor of national scientific & regulatory advice requests related to the development of new medicinal products for human/veterinary use • Chemical_pharmaceutical assessor of European scientific advice requests related to the development of new medicinal products for human use; in concertation with the Scientific Advice Working party (SAWP) of the European Medicines Agency (EMA) • Chemical_pharmaceutical assessor of clinical trial applications with investigational (i.e. non_licensed) and licensed medicinal products for human use including in vivo diagnostics) • Chemical_pharmaceutical assessor of paediatric investigation plans (PIPs) for drug products in concertation with the Committee (PDCO) of the European Medicines Agency (EMA) and the PDCO Formulation Working Group • Assisting chemical_pharmaceutical assessor of GMP inspections related to the manufacturing of radiopharmaceuticals; in collaboration with the Directorate_General Inspections of the Federal Agency for Medicines and Health Products (FAMHP) • Provision of scientific and regulatory support in the development and peer_review of (inter)national pharmaceutical legislation regarding radiopharmaceuticals, clinical trials, etc. in collaboration with different national and European regulatory authorities. • Development of Standard Operating Procedures (SOP's) for the assessment and provision of scientific and regulatory advice regarding medicinal products, paediatric drug products, medicinal products produced by genetically modified organisms, etc.
 - Country: Belgium
3. Employer: federal agency for medicines and healthcare products (FAMHP)
 - Start date: 042009
 - End date: 042017
 - Position: Head of the Unit for national scientific_regulatory advice & knowledge management
 - Activities: Operational and strategic management of the Unit for national scientific & technical/regulatory advice & knowledge management of the FAMHP
 - Country: Belgium
4. Employer: federal agency for medicines and health products
 - Start date: 052017
 - End date:
 - Position: Head of the national Innovation Office & Scientific_Regulatory Advice Unit
 - Activities: • Operational and strategic management of the national Innovation Office and Unit for national scientific & technical/regulatory advice of the FAMHP • Member of the "EU Innovation Offices Network (EU IN)", coordinated by the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA), (March 2015 – present) • Member of the EU IN's "Borderline & Classification working group" (i.e. the former HMA's "Medicine for paediatric, orphan, borderline and combination products co_ordination working group" coordinated by the EU IN and the European Medicines Agency (EMA), (November 2015 – present) • Alternate Member of the MDCG "Borderline & Classification working group (BCWG)" coordinated by the Medical Device Coordination Group of the European Commission, (March 2018 – present) • Member of the MDCG "New Emerging Technologies working group (NET)" coordinated by the Medical Device Coordination Group (MDCG) of the European Commission, (February 2019 – present) • Member of the Internal Market Committee group "Artificial Intelligence & Digital Economy" coordinated by the Interministerial Economy Commission (IEC) of the Federal Public Service of Economy in Belgium, (February 2019 – present) • Member of the High Level Working Group on Competitiveness and Growth van HLG COMPGROW, Directorate A – Artificial Intelligence & Digital Industry, (February 2019 – present) • Member of the Directorate_General for Communications Networks, Content and Technology of the European Commission (May 2018 – Present)
 - Country: Belgium

Education
and
training

1. Subject: Faculty of Pharmaceutical Sciences (Gent University)
 - Start date: 091995
 - End date: 061998
 - Qualification: Master in Pharmaceutical Sciences
 - Organisation:
 - Country: Belgium
2. Subject: Faculty of Pharmaceutical Sciences (Gent University)

- Start date: 091998
- End date: 042004
- Qualification: PhD in Pharmaceutical Sciences
- Organisation:
- Country: Belgium

Additional information

Publications

PUBLICATIONS IN INTERNATIONAL PEER REVIEWED JOURNALS 1. Lahorte C., Dumont F., Slegers G., Van De Wiele C., Dierckx R.A., and Philippé J., Synthesis and stability of 123I-labelled annexin V: A potential agent for SPECT imaging of apoptotic cells, *J. Labelled Comp. Radiopharm.* 43 (7), 739-750, 2000. 2. De Sutter Taeymans Y., Dierckx R.A., and Slegers G., Cell death in myocardial infarction, *Lancet* 356 (9239), 1439-1440, 2000. 3. Lahorte C., Slegers G., Philippé J., Van Dierckx R.A., Synthesis and in vitro evaluation of 123I-labelled human recombinant annexin V, *Biomol. Eng.* 17 (2), 51-53, 2001. 4. Van de Wiele C., Lahorte C., Boerman O., Goethals I., Slegers G., and Dierckx R.A., Nuclear Medicine Imaging to predict response to radiotherapy: a review, *Int. J. Radiat. Oncol. Biol. Phys.* 2003. 5. Lahorte C., Van de Wiele C., Bacher K., Van den Bossche B., Thierens H., Van Belle S., Slegers G., and Dierckx R.A., Biodistribution and dosimetry studies of 123I-labelled human recombinant annexin V in mice and humans, *Nucl. Med. Commun.*, 24, 871-880, 2003. 6. Van de Wiele C., Lahorte C., Vermeersch H., Loose D., Mervillie K., Steinmetz N.D., Cuvelier C.A., Slegers G., and Dierckx R.A., Quantitative tumour apoptosis imaging using 99mTc-HYNIC-Annexin_V single photon emission computed tomography, *J. Clin. Oncol.*, 21 (18), 3483-3487, 2003. 7. Vandenbulcke K., Devos F., Offner F., Philippé J., Apostolidis C., Molinet R., Nikula T.K., Bacher K., Dierckx R.A., Lahorte C., Thierens H., Dierckx R.A., and Slegers G., In vitro evaluation of 213Bi-Rituximab versus external gamma irradiation for the treatment of B-CLL, biological efficacy with respect to apoptosis induction and chromosomal damage, *Eur. J. Nucl. Med. Mol. Imaging*, 30 (10), 1357-1364, 2003. 8. Vermeersch H., Lahorte C., Mervillie K., Dierckx R.A., Steinmetz N.D., Vanderheyden J.L., Cuvelier C.A., Slegers G., and Van de Wiele C., 99mTc-HYNIC Annexin_V imaging of head and neck carcinoma, a comparison with computerized tomography, *Nucl. Med. Commun.*, 25 (3), 259-263, 2004. 9. Lahorte C., Bacher K., Burvenich I., Coene E., Offner F., Potter Ch., Thierens H., Van de Wiele C., Dierckx R.A., and Slegers G., Radiolabelling, biodistribution and dosimetry of 123I-MAB 14C5: A new monoclonal antibody for radioimmunodetection of tumour growth and metastasis in vivo, *J. Nucl. Med.*, 45 (6), 1065-1073, 2004. 10. Cornelissen B., Thonissen T., Kersemans V., Van de Wiele C., Dierckx R.A., and Slegers G., Influence of farnesyltransferase inhibitor treatment on epidermal growth factor receptor status, *Nucl. Med. Biol.*, 31 (6), 611-616, 2003. 11. Vermeersch H., Mervillie K., Lahorte C., Loose D., Dierckx R.A., Steinmetz N., Cuvelier C., Slegers G., and Van de Wiele C., Relationship of 99mTc-HYNIC Annexin_V microvessel density, Fas_L and MMP_9 expression, and the number of tumour-infiltrating lymphocytes in head and neck carcinoma, *Eur. J. Nucl. Med. Mol. Imaging*, 31 (7), 1016-1021, 2004. 12. Vermeersch H., Ham H., Rottey S., Lahorte C., Corsetti F., Dierckx R.A., Steinmetz N., and Van de Wiele C., Intraoperative and day-to-day reproducibility of quantitative 99mTc-HYNIC Annexin_V imaging in head and neck carcinoma, *Cancer Biother. Radiopharm.* 19 (2), 205-210, 2004. 13. Van de Wiele C., Steinmetz N., Van De Wiele C., Dierckx R.A. and Slegers G., Apoptosis detecting radioligands: Current state of the art and future perspectives (review article), *Eur. J. Nucl. Med. Mol. Imaging*, 31 (6), 887-919, 2004. 14. Cornelissen B., Lahorte C., Kersemans V., Capriotti G., Bonanno E., Signore A., Van De Wiele C., R.A. and Slegers G., In vivo apoptosis detection with radiolabelled Annexin V in LoVo tumour bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy, *Nucl. Med. Biol.*, 32 (3), 233-239, 2005. 15. Lancel S., Pettillot P., Stebach N., Lahorte C., Danze P.M., Vallet B., Marchetti P., Nevière R., Apoptosis factors and myocardial dysfunction in endotoxemic rats, *Crit. Care Med.* 33(3), 492-496, 2005. 16. Pettillot P., Lahorte C., Bonanno E., Signore A., Lancel S., Nevière R., Marchetti Ph., Vallet B., Slegers G. and Nevière R., Annexin V detection of lipopolysaccharide-induced cardiac apoptosis, *Shock*, 27 (1), 69-74, 2007. 17. Rottey S., Vakaet L., Lahorte C., Vermeersch H., Van Belle S. and Van de Wiele C., 99mTc-HYNIC Annexin_V imaging of tumors and its relationship to response to radiotherapy, *Q. J. Nucl. Med. Mol. Imaging*, 51 (2), 182-188, 2007. PUBLICATIONS IN SCIENTIFIC BOOKS 1. Arano. Y., Boersma H., Casaco, A., Castiglia, S., Signore A., Solanki K. and Wadhwa M., Clinical Translation of Radiolabelled Monoclonal Antibodies and Peptides, IAEA Human Health Series No. 8, International Agency (Vienna), ISBN 978_92_0_108809_3, ISSN 2075_3772, (<http://www.iaea.org/books>), 2009. PUBLISHED GUIDELINES 1. Janssens W., Lahorte C., and Slegers G., Guidance to the conduct of exploratory (phase 0) trials in Belgium, (https://www.famhp.be/sites/default/files/exploratory_guideline_clinical_trials_in_belgium_v3_07_06_2016_2.pdf), 2007 (version 1) & 2012 (version 2). 2. Willemse Pauwels K., Goossens M., Baldo A., Delgado R., Lenaers A., Lahorte C., Overview of procedures for submitting an application for clinical trials with GMO medicinal products and veterinary use in Belgium, (http://www.fagg.afmps.be/en/human_use/medicines/medicines/scientific_technical_advice/regulation), 2015. HEALTH CARE PRODUCT ASSESSMENT (HTA) STUDIES 1. Contributing expert to the HTA Study 2016_01 "Responsible use of high_risk medical devices: the example of 3D printed medical devices", coordinated by the Belgian Health Care Knowledge Centre (KCE), KCE report 297A, (https://www.kce.fgov.be/en/responsible_use_of_high_risk_medical_devices_the_example_of_3d_printed_medical_devices), January 16th 2018. INTERVIEWS 1. Interview regarding "The implementation of a national Innovation office at the Federal Agency for Medicines and Healthcare Products", Pharma.Be newsletter nr. 10, (http://pharma.be/nl/news/actualiteit/103_fagg_lahorte.html), May 19th 2017. 2. Video interview with Pharma.Be regarding patient involvement in clinical research and scientific advice procedures, presented at the Pharma.Be's Clinical Trials Forum 2019 (https://www.youtube.com/watch?v=z_J7NVFR7g&feature=youtu.be), KU Leuven Interview regarding "Innovation in market access in Belgium and the EU: Raising awareness about the usefulness and necessity of policy partnership", Master Thesis from Alicia Noyez, promoters Prof. Dr. Isabelle HUYS (KU Leuven) and Dr. Katrien De Groote (INNOSENS), March 22nd 2021. 4. Interview with the Embassy in Brussels regarding "Pharmaceutical Management systems in Belgium and the EU" in view of the implementation of a Canadian Drug Agency Transition Strategy, October 13th 2021. 5. Interview with Deloitte Consulting on behalf of Flanders Investment & Trade (FIT) regarding "advanced (immuno)therapies: identifying the gaps in the Flemish immunotherapy ecosystem by mapping the existing capabilities and benchmarking these with selected foreign hotspots", Monitor Deloitte, February 2022. 6. Interview with Erasmus University Rotterdam regarding "the accessibility of repurposed drug products" as part of the master thesis from Amy Bouman, Interview with the Wallonia Export and Investment Agency (AWEX) regarding "Introduction to the regulatory system in Europe and the role of the Belgian Agency for Innovation and Health Products", presented at the BioPlus_Interphex Korea 2022 life science event in Seoul (https://www.bioplusinterphex.co.kr/en_us/conference/SessionDetail.2886.156729.business_session_embassy_of_belgium_introduction_to_the_regulatory_system_in_europe.html), in collaboration with the Belgian Agency for Innovation and Health Products, August 3rd 2022. PROCEEDINGS OF INTERNATIONAL PEER REVIEWED CONFERENCES 1. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Synthesis and in vitro evaluation of 123I-labelled human recombinant annexin V, 9th European Congress on Biotechnology (ECB 9), July 11-15, 1999, Brussels, Belgium. 2. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Synthesis, biodistribution and dosimetry studies of 123I-labelled human recombinant annexin V in mice: A potential SPECT ligand for visualisation of apoptotic cells, 9th Symposium of the International Society of Radiolabelled blood elements (ISORBE), October 20-23, 1999, Rio De Janeiro, Brazil, *Nucl. Med. Commun.* 20 (10), p. 948, 1999. (poster presentation) 3. Brans B., Lahorte C., Jacobs F., Offner F., Slegers G., Thierens H., and Van de Wiele C., and Dierckx R.A., Synthesis, biodistribution and dosimetry studies of 123I-labelled human recombinant annexin V in mice: A potential SPECT ligand for visualisation of apoptotic cells, 9th Symposium of the International Society of Radiolabelled blood elements (ISORBE), October 20-23, 1999, Rio De Janeiro, Brazil, *Nucl. Med. Commun.* 20 (10), p. 948, 1999. (poster presentation) 4. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., Van De Wiele C., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 5. Cornelissen B., Thonissen T., Kersemans V., Van de Wiele C., Signore A., and Slegers G., In vivo visualization of farnesyltransferase inhibitor induced apoptosis in tumour bearing mice using radiolabelled Annexin V, 12th European Symposium on Radiopharmacy and Radiopharmaceuticals (ESRR), September 9-12, 2004, Gdansk, Poland, Congress Proceedings, 2004. (oral presentation) 6. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 7. Cornelissen B., Thonissen T., Kersemans V., Van de Wiele C., Signore A., and Slegers G., In vivo visualization of farnesyltransferase inhibitor induced apoptosis in tumour bearing mice using radiolabelled Annexin V, 12th European Symposium on Radiopharmacy and Radiopharmaceuticals (ESRR), September 9-12, 2004, Gdansk, Poland, Congress Proceedings, 2004. (oral presentation) 8. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 9. Cornelissen B., Thonissen T., Kersemans V., Van de Wiele C., Signore A., and Slegers G., In vivo visualization of farnesyltransferase inhibitor induced apoptosis in tumour bearing mice using radiolabelled Annexin V, 12th European Symposium on Radiopharmacy and Radiopharmaceuticals (ESRR), September 9-12, 2004, Gdansk, Poland, Congress Proceedings, 2004. (oral presentation) 10. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 11. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 12. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 13. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 14. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 15. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 16. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 17. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 18. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 19. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 20. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 21. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 22. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 23. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 24. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 25. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 26. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 27. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 28. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 29. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 30. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 31. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 32. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 33. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 34. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 35. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 36. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 37. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 38. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 39. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 40. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 41. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 42. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 43. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 44. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 45. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 46. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 47. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 48. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 49. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 50. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 51. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 52. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 53. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 54. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 55. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 56. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 57. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 58. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 59. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 60. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 61. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 62. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 63. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 64. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 65. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 66. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 67. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 68. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 69. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 70. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 71. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 72. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 73. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 74. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 75. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 76. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 77. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 78. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 79. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 80. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 81. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 82. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 83. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 84. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 85. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 86. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 87. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 88. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting of the International Society of Radiopharmaceuticals (ISR), July 15-17, 2004, Gent, Belgium, Congress Proceedings, 2004. (invited oral presentation) 89. Lahorte C., Dumont F., Slegers G., Van De Wiele C., De Sutter J., and Slegers G., Radiopharmaceuticals for apoptosis imaging: current state of the art and future perspectives, 17th Meeting

Association of Nuclear Medicine (EANM), August 31 _ September 4, 2002, Vienna, Austria, Eur. J. Nucl. Med. Mol. Imaging 29 (Suppl. 1), S91, OS164, 2002. (oral presentation) 11. Lahorte C., Burvenich I., Bacher K., Thierens H., Coene E., Schelfhout V., Cuvelier C., and Slegers G., Synthesis, biodistribution and dosimetry of the 123I-labelled anti-HER2/neu antibody: A potential SPECT_ligand for radioimmunodetection of tumour growth and metastasis in vivo, 15th Annual congress of the European Association of Nuclear Medicine (EANM), August 31 _ September 4, 2002, Vienna, Austria, Eur. J. Nucl. Med. Mol. Imaging 29 (Suppl. 1), S77, OS112, 2002. (oral presentation) 12. Pétillot P., Nevière R., Marchetti P., Slegers G., and Vallet B., Endotoxin_induced myocardial apoptosis and cyclosporin A, 15th Annual Congress of the European Society of Nuclear Medicine (ESNM), September 29 _ October 2, 2002, Barcelona, Spain, Intensive Care Med. 28 (Suppl. 1), S94, nr. 356, 2002. (poster presentation) 13. Lahorte C., Marchetti Ph., Bonanno E., Signore A., and Slegers G., Therapeutic evaluation of caspase inhibitors with 123I_Annexin V in a rat model of endotoxin_induced myocardial apoptosis, 16th Meeting of the International Research Group in Immunoscintigraphy and Immunotherapy (IRIST): "Peptide radiopharmaceuticals in diagnosis and cancer and inflammation/infection", May 8_10, 2003, Capri, Italy, Cancer Biotherapy & Radiopharmaceuticals 18 (2), p. 288_289, 2003. (poster presentation) 14. Lahorte C., Vermeersch H., Loose D., Mervillie K., Steinmetz N.D., Vanderheyden J.L., Cuvelier C.A., Slegers G., and Dierckx R.A., Quantitative tumour apoptosis imaging using 99mTc_HYNIC_Annexin single photon emission computerized tomography, 16th Annual congress of the European Association of Nuclear Medicine (EANM), 2003, Amsterdam, The Netherlands, Eur. J. Nucl. Med. Mol. Imaging 30 (Suppl. 2), S180, OS144, 2003. (oral presentation) 15. Vermeersch H., Loose D., Lahorte C., Dierckx R.A., Steinmetz N.D., Vanderheyden J.L., Cuvelier C.A., Slegers G., and Van de Wiele C., 99mTc_HYNIC_Annexin_V imaging of primary head and neck cancer: comparison with computerized tomography, 16th Annual congress of the European Association of Nuclear Medicine (EANM), August 23_27, 2003, Amsterdam, The Netherlands, Eur. J. Nucl. Med. Mol. Imaging 30 (Suppl. 2), S180, OS145, 2003. (oral presentation) 16. Pétillot P., Lahorte C., Nevière R., Marchetti P., Slegers G., and Vallet B., Imaging of LPS_induced myocardial apoptosis with 123I_annexin V relevant?, 16th Annual Congress of the European Society of Intensive Care Medicine (ESICM), 2003, Amsterdam, The Netherlands, Intensive Care Med. 29 (Suppl. 1), S29, nr. 95, 2003. (poster presentation) 17. Pétillot P., Lancel S., Lahorte C., Bonanno E., Vallet B., Marchetti P., and Nevière R., Simultaneous alterations of apoptosis regulatory molecules and myocardial function in septic rats, 17th Annual Congress of Intensive Care Medicine (ESICM), October 10_14, 2004, Berlin, Germany, Intensive Care Med. 30 (Suppl. 1), S167, nr. 643, 2004. (poster presentation) 18. Verbruggen A., Musch G., Radiotracers for clinical trials: EU legislation, 13th European Symposium European Symposium on Radiopharmacy and Radiopharmaceuticals (ESSR), March 30 _ April 2, 2006, Lucca, Italy, Q. J. Nucl. Med. 50 (Suppl. 1 to issue nr. 1), p. 27_28, 2006. (invited oral presentation) CONTRIBUTIONS TO NATIONAL SCIENTIFIC CONFERENCES 1. Lahorte C., Dumont F., Slegers G., Thierens H., Van De Wiele C., and Dierckx R.A., In vivo evaluation of 123I_annexin V in mice: A potential imaging of apoptotic cell death, 10th BGNG Symposium (Belgisch Genootschap voor Nucleaire Geneeskunde), May 19_20, 2001, Knokke, Belgium, Belgisch Tijdschrift voor Nucleaire Geneeskunde 23, p. 162, 2001. (poster presentation) 2. Pétillot P., Lahorte C., Nevière R., Marchetti Ph., Slegers G., and Vallet B., Détection isotopique myocardique induite par le sepsis, 43ème Congrès National de la Société Française d'Anesthésie et de Réanimation (SFAR), September 20_23, 2001, Paris, France, Annales Françaises d'Anesthésie Réanimation 20 (Suppl. 1), 309s, R538, 2001. (poster presentation) 3. Pétillot P., Lahorte C., Nevière R., Marchetti Ph., Slegers G., and Dierckx R.A., Détection de l'apoptose myocardique induite par le Lipopolysaccharide (LPS), 44ème Congrès National de la Société Française d'Anesthésie et de Réanimation (SFAR), September 19_22, 2002, Paris, France, Annales Françaises d'Anesthésie Réanimation 21 (Suppl. 2), 272s, R169, 2002. (poster presentation) 4. Signore A., Lahorte C., Pétillot P., Marchetti Ph., and Slegers G., Detection of myocardial cell death by 123I_labelled annexin_V in rats with septic shock, 6th National congress of the Association of Nuclear Medicine (IANM), November 15_19, 2002, Genoa, Italy, Q. J. Nucl. Med. 46 (4) Suppl. 1, p. 20, 2002. (oral presentation) 5. Pétillot P., Lahorte C., Marchetti Ph., Slegers G., and Vallet B., La détection in vivo de l'apoptose myocardique induite par le LPS est-elle possible?, 45ème Congrès National de la Société Française d'Anesthésie et de Réanimation (SFAR), September 18_21, 2003, Paris, France, Annales Françaises d'Anesthésie Réanimation, 22 (Suppl. 2), 208s, R205, 2003. (poster presentation) 6. Pétillot P., Lahorte C., Bonanno E., Nevière R., Marchetti Ph., Slegers G., Signore A., Vallet B., Détection autoradiographique de l'apoptose myocardique induite par le LPS, 46ème Congrès National de la Société Française d'Anesthésie et de Réanimation (SFAR), April 17_18, 2004, Paris, France, Annales Françaises d'Anesthésie Réanimation, 23 (3), 221s, R68, 2004. (poster presentation)

Projects

PROJECT MANAGEMENT EXPERIENCE: • Development and implementation of the "alpha_emitters laboratory" within the Dept. of Nuclear Medicine, Gent University (2000 - present) • start_up of alpha_radioimmunotherapy in Non_Hodgkin's Lymphoma as part of a European research project, (September 1998 _ October 2001) • VirRAD project (Internet_based Virtual Radiopharmacy Learning Community), <http://www.virrad.eu.org>, EU_project no.: IST_2001_32291, (March 2002 _ August 2004) • Part-time member of the National Competent Authorities consortium for the Horizon 2020 project "SC1_HCO_05_2018: Strengthening regulatory sciences and supporting scientific advice (STARS)", a Coordination and Support Action on Training Academia in Regulatory Sciences and supporting regulatory scientific advice, <https://cordis.europa.eu/project/rcn/220223/factsheet/en>, (November 2017 - present) • Active follow up and involvement in the Safe and Timely Access to Medicines initiative of the EU Commission on repurposing of old drug products in collaboration with the Belgian Anticancer Fund (June 2018 - present) • Active involvement in the pilot project on Simultaneous National Scientific Advice (SNSA) coordinated by the EU_IN Working Group on SNSA, https://www.ema.europa.eu/en/human_regulatory_research_development/innovation_medicines#eu_innovation_network_section, (February 2020 - present) • Involvement as SNSA co_chair of the EU_IN in the Accelerating Clinical Trials in the EU (ACT EU) _ Delivering an EU clinical trials transformation initiative, https://www.ema.europa.eu/en/documents/regulatory_procedural_guideline/accelerating_clinical_trials_eu_act_eu_delivering_eu_clinical_trials_transformation_en.pdf, (April 2022 - present) • Co_author of an industrial project proposal for basic research, submitted to the Institute for the Advancement of Scientific and Technological Research (IWT), (February 2000) • Co_author of a project proposal for basic research, submitted to the Fund of Scientific Research (FWO - Vlaanderen), (January 2000) • Project leader within the FAMHP for the project "National Scientific Technical (eg. Regulatory) Advice" (April 2007 - April 2009) • Project leader within the FAMHP for the project "Knowledge Management" in collaboration with the HR and ICT departments of the FAMHP (September 2007 - Present) • Coordinator of the FAMHP platform for the international supply crisis for medical isotopes, in collaboration with the Federal Ministry of Health (March 2009 - present) • Project member for the transversal strategic communication, education and training of personnel, networking expertise, early phase drug development, development of an expertise database (December 2009 - present) • Member of the FAMHP working group on Medical Devices evaluation and expertise (June 2012 - present) • Member of the FAMHP working group on e-development (June 2014 - December 2016) • Member of the FAMHP working group on Radiopharmaceuticals (July 2015 - December 2016) • Project leader within the project "Implementation of a national Innovation Office" in view of implementing specific support mechanisms for SME's and academic research organisation innovation in pharmaceutical drug development and medical devices (January 2016 - Present) • Member of the FAMHP _ BeMedTech working group on clinical medical devices, in collaboration with the Belgian Federation of the Medical Technologies Industry BeMedTech), (September 2016 - present) • Member of the FAMHP working group on 3D printing technologies and contributing expert to the HTA Study 2016_01 "Responsible use of high_risk medical devices: the example of 3D printed medical devices", coordinated by the Belgian Health Care Knowledge Centre (KCE), KCE report 297A (May 2017 _ January 16th 2018) • Project member of the FAMHP project for disease_oriented patient organisations and umbrella organisations (eg. RadiOrg, Flemish Patient Platform, Wallonian Patients Ligue) in clinical research through scientific_regulatory advice procedures and evaluation of clinical trials applications (October 2017 - present) PATENT APPLICATIONS _ INTELLECTUAL PROPERTY PARTICIPATION in the feasibility study on: "Patentability of the 14C5 monoclonal antibody and its applications in nuclear medicine", in collaboration with the Dept. of Technology Transfer, Directorate of Research Management, Gent University and the Patent Attorney Office "De Clercq Brants & Partners", St._Martens_Latem (September 2007 - present) application concerning "Characterisation of the 14C5 antigen involved in cell substrate adhesion, invasion and metastasis of breast carcinoma cells", in collaboration with the Dept. of Technology Transfer, Directorate of Research Management, Gent University patent application file (Nr. 2001/0447) submitted to the Federal Government of Belgium, Economy, Division of Industrial Property, Brussels, (June 2001)

Memberships

• European Association of Nuclear Medicine (EANM), <http://www.eanm.org>, (May 2002 _ August 2004) • Society of Radiopharmaceutical Chemistry and Biology (Society of Radiopharmaceuticals), <http://www.imaging.wustl.edu/RadsciChemistry/SRCB>, (January 2002 _ August 2004) • International Research Group in Immunoscintigraphy and Immunotherapy (IRIST), <http://www.irist.org>, (May 2003 _ August 2004) • VirRAD project member (Internet_based Virtual Radiopharmacy Learning Community), <http://www.virrad.eu.org>, no.: IST_2001_32291, (March 2002 _ August 2004) • Chemical_pharmaceutical expert recognized by the European Medicines Agency (EMA), London, UK (October 2007 - present) • Belgian alternate member of the Paediatric Committee (PDCO) of the European Medicines Agency (EMA), (December 2007 - April 2008) • Belgian member of the Paediatric Committee formulation working group (PDCO FWG) of the European Medicines Agency (EMA), (December 2007 - June 2011) • Member of the Technological Radioisotopes (TRRI) of the RIZIV Institute, Brussels, regarding the common assessment for reimbursement of radiopharmaceuticals and radioisotopes, (March 2008 - present) • Member of the high_level expert group on medical radioisotopes (HLG_MR) of the Nuclear Energy Agency (NEA) at the OECD March 2009 _ 2017) • Member of the Innovation Offices Network working group, coordinated by the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA), (March 2015 - present) • Member of the HMA's "Medicines and device borderline and combination products co_ordination working group" coordinated by the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA), (November 2016 - 2018) • Alternate Member of the MDCG "Borderline & Classification working group (BCWG)" coordinated by the European Medicines Agency (EMA), (November 2016 - 2018) • Member of the MDCG "New Emerging Technologies working group (NETG)" coordinated by the European Medicines Agency (EMA), (March 2018 - present) • Member of the MDCG "New Emerging Technologies working group (NETG)" coordinated by the Medical Device Coordination Group (MDCG) of the European Commission, (February 2019 - present) • Member of the Internal Market Committee group on "Artificial Intelligence & Digital Economy" coordinated by the Interministerial Economy Commission (IEC) of the Federal Public Service of Economy in collaboration with the Working Group on Competitiveness and Growth van HLG COMPGROW, Directorate A - Artificial Intelligence & Digital Industry and the Directorate_General for Communications, Content and Technology of the European Commission (May 2018 - Present)

Other Relevant Information

COLLABORATIONSHIPS: • Collaboration with the European Institute for Transuranium Elements (ITU, Karlsruhe, Germany) regarding the implementation of the alpha_radioimmunotherapy in Non_Hodgkin's Lymphoma as part of a European research project (September 1998 _ October 2001) • Collaboration with the International Energy Agency (IAEA, Vienna) regarding the development of regulatory guidance for clinical development of radiolabelled biologicals, (October 2005 - January 2006) • Member of the FANC _ FAMHP working group on radiopharmaceuticals, in collaboration with the Federal Agency for Nuclear Control (FANC, Brussels), (April 2008 - present) • Collaboration with the European Clinical Trial Facilitation Group (CTFG) regarding the Euralex Vol 10 Guidance document on "Harmonized requirements for non-medical products in CTA submissions", (December 2008 - February 2009) • Collaboration with the Permanent Representation of Belgium to the European Union, Ministry of Health, the Federal Government Service of Economy, FANC, RIZIV and the Association of Imaging Producers and Equipment Suppliers (AIPES), EANM and the European Commission, regarding the international supply crisis for medical isotopes (March 2009 - present) • Collaboration with the Scientific Institute of Public Health (WIV), the Belgian Health Care Knowledge Center (KCE), the Federal Public Service Health, Food chain safety and environment (FOD VVVL), FANC and RIZIV regarding scientific_regulatory advice requests (April 2009 - present). • Collaboration with Flanders Investment Trade (FIT) regarding the provision of general and regulatory advice to foreign pharmaceutical and medical device / IVD companies exploring investments in Belgium (February 2015 - present). • Collaboration with the Belgian life science and healthcare associations FlandersBio, BioWin and Pharma.Be regarding the implementation of national support mechanisms for SME's / academic research centres

initiatives to stimulate innovation in the (pre)clinical development of medicinal products and healthcare products, (March 2016 – present). • Collaboration with the Working Group of the Belgian Biopharma platform and Federal Ministry of Health regarding the implementation of national innovation support mechanisms for the pharmaceutical industry, (June 2017 – present). • Collaboration with multiple disease-oriented patient organisations and umbrella organisations (eg. RadiOrg, F Platform, Wallonian Patients Ligue) at national level and patient experts at EU level. • Collaboration with the European Patients' Academy (EUPATI Belgium) for training of disease-oriented patient organisations at national level. • Collaboration with the Korean Trade – Investment Promotion Agency (KOTRA) regarding the general and regulatory guidance to Korean pharmaceutical and medical device / IVD companies exploring investments in Belgium (November 2018 – present). • Collaboration with the Innovation Task Force (ITF) of the European Medicines Agency: Active participation in ITF meetings with Innovators regarding new innovative drug production technologies used in clinical research, (May 2019 – Present) • Collaboration with the Belgian Patient Expert Centre (PEC) regarding patient engagement in early advice procedures related to clinical trials, (January 2022 – present) • Collaboration with the Wallonia Export and Investment Agency (AWEX) and the Brussels Hub Agency (HUB.Brussels) regarding the provision of general and regulatory guidance to foreign pharmaceutical and medtech companies exploring investments in Belgium (2022 – present) • Collaboration with the EMA, EU Commission, Heads of Medicine Agencies (HMA) and Clinical Trials Coordination Group (CTCG) regarding the “Clinical Trials in the EU (ACT EU) – Delivering an EU clinical trials transformation initiative”, (April 2022 – present)